# A Safety, Tolerability and Preliminary Efficacy Study of BBI-4000 in Subjects With Axillary Hyperhidrosis

> **NCT02058264** · PHASE1 · COMPLETED · sponsor: **Botanix Pharmaceuticals** · enrollment: 18 (actual)

## Conditions studied

- Hyperhidrosis

## Interventions

- **DRUG:** BBI-4000

## Key facts

- **NCT ID:** NCT02058264
- **Lead sponsor:** Botanix Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02
- **Primary completion:** 2014-08
- **Final completion:** 2014-09
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2022-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02058264

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02058264, "A Safety, Tolerability and Preliminary Efficacy Study of BBI-4000 in Subjects With Axillary Hyperhidrosis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02058264. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*